Vir Biotechnology (VIR) Scheduled to Post Earnings on Thursday

Vir Biotechnology (NASDAQ:VIR) is scheduled to issue its quarterly earnings data after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.96) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.13). Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The firm had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $7.53 million. During the same period in the prior year, the business posted ($1.45) EPS. The business’s quarterly revenue was down 19.0% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Stock Performance

VIR stock opened at $7.52 on Thursday. The firm has a 50 day moving average price of $7.89 and a 200-day moving average price of $8.94. Vir Biotechnology has a 52-week low of $7.12 and a 52-week high of $13.09. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1.88 and a beta of 0.46.

Insiders Place Their Bets

In related news, Director Janet Napolitano sold 12,190 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $7.80, for a total value of $95,082.00. Following the completion of the transaction, the director now owns 11,616 shares of the company’s stock, valued at approximately $90,604.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 15.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on VIR. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a report on Tuesday, August 20th. Barclays boosted their price objective on shares of Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.80.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).